Menu
← Oncology Approval Tracker
FDA DECISION ·
Nerlynx
neratinib · Puma Biotechnology
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds the option to start with a lower daily dose and escalate over the first two weeks before the full daily dose in existing HER2-positive breast cancer uses.
LAMPGEN ANALYSIS
Why it matters
The label incorporates a dosing option studied to improve management of neratinib-associated diarrhea.
What research teams should watch
Build the staged doses into dispensing and capture diarrhea, supportive treatment and whether escalation was completed.
PRIMARY RECORDS